Article ID Journal Published Year Pages File Type
5697707 Clinical Oncology 2017 7 Pages PDF
Abstract
Due to a lack of empirical research, few evidenced-based recommendations could be made with respect to a follow-up schedule of PSA testing for prostate cancer survivors following curative-intent treatment, or detailing diagnostic testing upon detection of biochemical recurrence. Accordingly, the GDG focused substantial effort on critical examination of the identified evidence, existing clinical practice guidelines and on obtaining clinical expertise consensus using a modified Delphi method. Overall, the recommendations embedded in this guideline reflect the best practice to date for the efficient and effective clinical follow-up care of prostate cancer survivors.
Related Topics
Health Sciences Medicine and Dentistry Oncology
Authors
, , , , , , , , ,